Abstract
Editorials1 June 1985Immunotherapy of Type I Diabetes MellitusGEORGE S. EISENBARTH, M.D., Ph.D.GEORGE S. EISENBARTH, M.D., Ph.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-6-846 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn most patients, type I diabetes results from autoimmune beta-cell destruction in the setting of a genetically determined predisposition (1). Approximately 95% of patients with type I diabetes express HLA antigens DR3 or DR4 or both (2), and within families, siblings with type I diabetes have in common at least one and often both HLA-haplotypes (3). In many patients, anti-islet antibodies precede overt diabetes. Several assays for anti-islet antibodies have been developed but the only assay that has shown prognostic significance measures binding of antibodies to non-fixed, frozen sections of normal human pancreas (4-8). Only a few research centers have...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call